Johnson & Johnson Shares Rise 5.9% as Revenue Forecast Tops $23.4B
Johnson & Johnson shares returned 5.9% last month versus a 1.1% gain for large-cap pharma peers, supported by unchanged consensus EPS of $2.68 for current quarter (–3.3% YoY) and revenue forecasts of $23.43 billion (+7%). Under its proprietary ranking, the stock carries a Hold rating (#3) and C valuation grade.
1. Stock Performance Metrics
Over the past month, Johnson & Johnson shares gained 5.9%, outpacing the Zacks S&P 500 composite’s 1.3% decline and the large-cap pharmaceuticals industry’s 1.1% advance. This relative strength highlights investor interest driven by stable fundamentals rather than news events.
2. Earnings and Revenue Estimates
Consensus EPS for the current quarter stands at $2.68, down 3.3% year-over-year, with no revision in the past 30 days. Revenue expectations for the same period total $23.43 billion (+7%), while full-year sales and EPS forecasts project $100.29 billion (+6.5%) and $11.54 per share (+7%), respectively.
3. Valuation Grade and Surprise History
The stock holds a Hold rating (#3) and a C valuation grade under its proprietary scoring, indicating fair value relative to peers. In the last reported quarter, J&J beat consensus by 1.84% on revenue and 1.23% on EPS, marking four consecutive quarters of positive surprises.